Upending the Treatment Paradigm in AML

Posted by Nathan Noll on Dec 19, 2017 9:40:13 AM

Sony introduced the Walkman in 1979. At the time, it was revolutionary, but when compared with the technology available today, it is woefully outmatched.


>
Read More

Multiple Myeloma at ASH 2017: Observations and Analysis

Posted by Josh Hattem on Dec 14, 2017 9:11:58 AM

There were 935 abstracts related to multiple myeloma accepted into the 2017 American Society of Hematology (ASH) Annual Meeting, or roughly one piece of new research for every 127 multiple myeloma patients in the U.S., according to the National Cancer Institute.


>
Read More

A Gut Check on the Role of Microbiome in Cancer

Posted by Pranav Srivastava on Jul 26, 2017 11:16:51 AM

Matt Furlow co-authored this post with Pranav Srivastava.

In the novel A Wind in the Door by Madeleine L’Engle, the main character’s younger brother gets sick when fictional symbiotic entities within his mitochondria called farandolae fail to work together to prevent illness. My co-author and I were reminded of that story as we looked for parallels for the symbiotic nature of gut flora and the notion that the gut microbiome can have significant implications on health—a promising area of research that should be on the radar of oncology companies looking to expand their portfolios.


>
Read More

Beyond PD-L1: In Search of Better Biomarkers

Posted by Sharon Karlsberg on Jul 14, 2017 8:00:00 AM

Tyler Vogt co-wrote this blog post with Sharon Karlsberg. 

Since their first approval in 2014, PD-L1 and PD-1 checkpoint inhibitors have become the backbone therapy in multiple tumor types: melanoma, bladder cancer and non-small-cell lung cancer (NSCLC). Although only 20 to 35% of patients respond to these therapies, approvals in melanoma, bladder cancer and second-line lung cancer didn’t require an associated diagnostic test for PD-L1 status. Until the failure of BMS’s CheckMate-026 trial in first-line NSCLC, oncologists were asking the question, “Should I test for PD-L1?”


>
Read More